# 2026-13533: FDA Seeks Input on Biologics License Paperwork

2026-13533, Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-07-06, effective Either electronic or written comments on the collection of information must be submitted by September 4, 2026.; PRIA reads it as touching household money (as of 2026-07-13).

- Canonical: https://policyrisk.com/federal-register/2026-13533
- As of: 2026-07-13
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-13533
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 41046
- Published: 2026-07-06
- Effective: Either electronic or written comments on the collection of information must be submitted by September 4, 2026.
- Comments close: 2026-09-04
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-07-13

## In one line

FDA Seeks Input on Biologics License Paperwork

## Summary

The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection activities associated with Biologics License Applications, Procedures and Requirements.

## Effects PRIA read

- Paperwork Burden for Biologics Makers: cost, high. If you are a licensed manufacturer of biological products, the FDA estimates there are 371 respondents who will file an estimated 70,946 total annual responses, which together require about 860,170 total burden hours each year. These reporting and recordkeeping requirements come from 21 CFR parts 6…
- Standard Forms and Electronic Filing Rules: benefit, medium. The FDA requires use of specific forms for BLAs, including Form FDA 356h, Form FDA 2252, Form FDA 2253, and Form FDA 3674, and permits submission via the Electronic Submission Gateway (ESG) for which respondents must create and maintain a user account. FDA states that using Form FDA 356h helps ensu…
- Notify Agents on License Suspension: cost, low. Under 21 CFR 601.6(a), licensed firms must notify selling agents and distributors if a license is suspended. FDA estimates this third-party disclosure will result in about 20 disclosures (0.33 hours each) totaling roughly 7 hours annually for applicable respondents.
- Net Annual Response and Hour Adjustments: cost, medium. FDA reports cumulative adjustments that result in an average decrease of 2,168 responses and an average increase of 29,133 burden hours annually for this collection. These adjustments change how much time respondents must spend on their BLA-related submissions each year.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-13533 on federalregister.gov](https://www.federalregister.gov/documents/2026/07/06/2026-13533/agency-information-collection-activities-proposed-collection-comment-request-biologics-license)
- [2026-13533 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-07-06/pdf/2026-13533.pdf)

## Related
- [Previous: 2026-13532, Self-Regulatory Organizations; NYSE American LLC; Notice of Filing and Immediat…](https://policyrisk.com/federal-register/2026-13532)
- [Next: 2026-13534, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2026-13534)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-13533 (as of 2026-07-13).
